Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Study in Hematologic Malignancies Treated with Duvelisib
2016-000848-34Phase 2Completed
- Sponsor
- Verastem Oncology
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of duvelisib in hematopoietic malignancies, sponsored by Verastem Oncology. Primary endpoints: Adverse events and Safety laboratory test values. Started Jan 2022; status: completed.
02
Drugs
duvelisib
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on 2016-000848-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000848-34.